Back

Outcomes are equally poor for patients with suspected heart failure and raised natriuretic peptides, regardless of whether heart failure is confirmed or excluded by a specialist

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Alice Zheng

Portsmouth Hospitals NHS Trust, Portsmouth (United Kingdom of Great Britain & Northern Ireland)

22 More presentations in this session

Presentation thumbnail
Nationwide trends in prevalence and incidence of and 3-year mortality in hospitalized heart failure patients in Taiwan (2010-2015): lingering hazards remain
Professor T. Wang (Taipei, TW)
Abstract Slides
Presentation thumbnail
Modes of death in cardiac amyloidosis
Ms C. Binder (Vienna, AT)
Abstract
Presentation thumbnail
Liver-specific microRNA-122 as a prognostic biomarker in patients with chronic heart failure
Associate Professor S. Stojkovic (Vienna, AT)
Abstract Slides
Presentation thumbnail
Genetics in heart failure prognosis: does it make a difference?
Mr A. Ulitin (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Economic impact of ivabradine use in the vulnerable phase: results from the ROCI registry
Doctor C. Saldarriaga (Medellin, CO)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources